Arirang TV Showcases the Future of Korea's Sports Innovation to the World

- From AI Motion Analysis to Functional Materials: 20 Promising Korean Sports Companies Eye Global Expansion

- "K-Sports Beyond" Premieres Thursday, October 15, 2026, at 9 a.m. (KST), airing in 140 countries worldwide

SEOUL, South Korea, Oct. 12, 2026 /PRNewswire/ -- Arirang TV (CEO Kim Tae-jeong) will premiere "K-Sports Beyond," a global program showcasing the advanced technology and potential of Korea's sports industry, for audiences around the world on Thursday, October 15.

The special program was developed to support the overseas expansion of 20 promising Korean small and medium-sized sports enterprises amid the global K-culture boom. It focuses on innovative products spanning advanced technologies and functional sportswear, including sports safety equipment, recovery solutions, AI-powered motion analysis and health management, smart fitness, taekwondo IT convergence, and screen sports.

Notably, popular K-pop idols — FIFTY FIFTY's Chanelle Moon and Athena, TEMPEST's Hanbin, and LUN8's Chael and Takuma — along with foreign TV personalities visited the set and experienced the equipment firsthand, helping to showcase the technological prowess of K-sports to a global audience.

The main episodes cover: Athlete Protection (Godo, SMARTHADA), Recovery (GHIWELL, WithsunBio), Space Innovation (GSTG, Goodrunner company), Ball Sports & Park Golf (NASSAU, DAWON SOLUTECH), AI Body Shape Management (ONESOFTDIGM, 3i), Fitness Equipment (DRAX, LEXCO), Functional Materials (SHOEALLS, ANYHORSE), Community Sports (HOLLYWOOD, Myplay company), Sports IT (PSYNET, AITKD), and Screen Golf (XGolf, MOAIS).

"This program will show how Korea's strength as an ICT powerhouse is expanding across the sports industry," an Arirang TV official said. "By reaching 169 million households in 140 countries, Arirang TV aims to strengthen the global presence of Korea's sports industry."

Broadcast Information

- Arirang TV : K-Sports Beyond

- YouTube : https://www.youtube.com/@BeMyKorea

SOURCE Arirang TV

Share this article

VALLETTA, Malta, Oct. 12, 2026 /PRNewswire/ -- On the sidelines of the 2026 WTTC Global Summit held in Malta, Carlo Micallef, CEO of the Malta Tourism Authority, met with Edison Chen, Vice President of Trip.com Group, for talks on China–Malta tourism cooperation. Witnessed by Jo Etienne Abela, Malta's Minister for Tourism, the Malta Tourism Authority and Trip.com Group formally signed the 2026–2029 Strategic Cooperation Memorandum of Understanding.

The signing of the Strategic Cooperation MOU marks a further deepening of the strategic partnership between the Malta Tourism Authority and Trip.com Group. Over the next three years, the two parties will carry out in-depth cooperation in destination promotion, tourism product diversification and sustainable tourism.

"Malta is committed to diversifying its source markets, and China is the most important emerging market in our strategic plans," said Carlo Micallef, CEO of the Malta Tourism Authority. "Our partnership with Trip.com Group will help us reach high-value travellers in China and around the world more precisely, and showcase Malta's unique appeal as a premium Mediterranean tourism destination."

Edison Chen, Vice President of Trip.com Group, said, "Malta is a vibrant destination, offering a wealth of cultural and premium experiences, and excellent connectivity. Our data shows a 60% growth in inbound travel bookings to Malta, underscoring its growing appeal among global travellers. By combining Trip.com Group's global reach and platform technology with Malta's unique offerings, we are excited to further boost tourism in Malta, inspiring more travellers from Asia and around the world to discover its beauty."

Malta Accelerates Its Push into the Asian Market

Malta is actively expanding into the Asian market, with plans to raise the share of arrivals from outside the EU to 40% within the next decade. Carlo Micallef, CEO of the Malta Tourism Authority, said that Malta is advancing tourism cooperation discussions with China and several other Asian countries. Although Schengen visa requirements remain a short-term challenge, the market potential is immense.

Trip.com Group's platform coverage advantages across the world's major source markets, together with its leading big-data and AI-supported capabilities, will help Malta enhance its brand influence as a premium tourism destination. With a large presence in Asia, Europe and across global markets, Trip.com Group is highly strategically aligned with the Malta Tourism Authority's market diversification strategy.

The 2026 WTTC Global Summit was held from 7 to 9 October at the Mediterranean Conference Centre in Valletta, bringing together tourism industry CEOs and senior government leaders from more than 100 countries. The signing is one of the significant cooperation outcomes achieved during the Summit. Over the next three years, the two parties will leverage the technological capabilities and data insights of Trip.com Group's global platforms, combined with the Malta Tourism Authority's in-depth understanding and integration of local tourism resources, to continuously optimise promotional strategies and position Malta as a highly attractive Mediterranean tourism destination for global travellers.

About Trip.com Group

Trip.com Group is a global travel service provider comprising of Trip.com, Ctrip, Skyscanner, and Qunar. Across its platforms, Trip.com Group helps travellers around the world make informed and cost-effective bookings for travel products and services and enables partners to connect their offerings with users through the aggregation of travel-related content and resources, and an advanced transaction platform consisting of apps, websites and 24/7 customer service centres. Founded in 1999 and listed on NASDAQ in 2003 and HKEX in 2021, Trip.com Group is on the mission "to pursue the perfect trip for a better world". Find out more about Trip.com Group here: group.trip.com.

Follow us on: X , Facebook , LinkedIn , and YouTube.

SOURCE Trip.com Group

Share this article

Red Rock Resorts Announces Date of Third Quarter 2026 Conference Call and Earnings Release Date

LAS VEGAS, Oct. 12, 2026 /PRNewswire/ -- Red Rock Resorts, Inc. ("Red Rock Resorts", "we" or the "Company") (NASDAQ: RRR) announced today that it will release the Company's financial results for the third quarter 2026 on Tuesday, November 3, 2026 and will hold a conference call on the same day at 4:30 p.m. ET (1:30 p.m. PT). The conference call will consist of prepared remarks from the Company and will include a question and answer session.

To listen to the conference call, please dial into the conference operator no later than 4:15 p.m. ET (1:15 p.m. PT) at (888) 317-6003 using the passcode: 6050941. For those of you dialing internationally, your dial in number is (412) 317-6061. A live audio webcast of the call will also be available at www.redrockresorts.com.

A replay of the call will be available through November 10, 2026, by dialing in at (855) 669-9658 or internationally at (412) 317-0088 using conference ID: 9807317. An audio archive of the call will also be available at www.redrockresorts.com.

About Red Rock Resorts

Red Rock Resorts is a holding company that owns an indirect equity interest in and manages Station Casinos LLC ("Station Casinos"). Station Casinos is the leading provider of gaming, hospitality and entertainment to the residents of Las Vegas, Nevada. Station Casinos' properties, which are located throughout the Las Vegas valley, are regional entertainment destinations and include various amenities, including numerous restaurants, entertainment venues, movie theaters, bowling and convention/banquet space, as well as traditional casino gaming offerings such as video poker, slot machines, table games, bingo and race and sports wagering. Station Casinos owns and operates Red Rock Casino Resort Spa, Green Valley Ranch Resort Spa Casino, Durango Casino Resort, Palace Station Hotel & Casino, Boulder Station Hotel & Casino, Sunset Station Hotel & Casino, Santa Fe Station Hotel & Casino, Wildfire Rancho, Wildfire Boulder, Wildfire Sunset, Wildfire Valley View, Wildfire Anthem, Wildfire Lake Mead, Wildfire on Fremont and Seventy Six by Station Casinos (North Lamb, Aliante, Union Village, Tropicana, Fort Apache, Park Highlands, and Silverado Ranch). Station Casinos also owns a 50% interest in Barley's Casino & Brewing Company, Wildfire Casino & Lanes and The Greens.

Investors:

Red Rock Resorts

Stephen L. Cootey

(702) 495-3550

Media:

Michael J. Britt

(702) 495-3693

[email protected]

SOURCE Red Rock Resorts, Inc.

Share this article

ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention

SHANGHAI, Oct. 12, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company to initiate a phase II clinical trial for influenza prevention in general population in the United States.

Addressing Gaps in Influenza Prevention

Seasonal vaccination remains central to influenza prevention. However, changes in circulating influenza viruses and variability in individual immune response can limit vaccine protection, particularly among older adults and people who are immunocompromised. Additional preventive approaches could help address these unmet needs.

According to the U.S. Centers for Disease Control and Prevention (CDC), despite the availability of influenza vaccines, the 2025–2026 influenza season resulted in at least 32 million illnesses, 380,000 hospitalizations and 24,000 deaths in the United States.

About AK0406

AK0406 is a novel AFC drug discovered and developed by ArkBio. By precisely conjugating multiple potent small-molecular antivirals to an antibody Fc domain, AK0406 is designed to combine direct antiviral activity with Fc-mediated immune clearance to prevent influenza, with potential therapeutic applications.

In preclinical studies, AK0406 demonstrated broad-spectrum and highly potent antiviral activity against both influenza A and B strains. It has also been optimized for its pharmacokinetics (PK) properties and GMP manufacturing process.

Global Clinical Development

In February 2026, AK0406 received approval from a Human Research Ethics Committee (HREC) in Australia to initiate a phase I clinical trial. In July 2026, ArkBio announced that enrollment and dosing of healthy adult participants had been completed across all cohorts and that the study had entered the follow-up phase.

In August 2026, National Medical Products Administration (NMPA) of China cleared the IND application for AK0406 for influenza prevention. The FDA clearance marks a further milestone in the global clinical development of AK0406.

Planned U.S. Phase II Trial

The U.S. phase II clinical trial will be a multicenter, randomized, double-blind, placebo-controlled study in adults during an influenza season. Its primary objective is to evaluate AK0406 for influenza prevention. The study will also assess safety, tolerability, PK and immunogenicity. The resulting data will inform AK0406's future global development strategy.

ArkBio plans to continue discussions with the FDA and the Center for Drug Evaluation (CDE) of China's NMPA to advance phase II development in the United States and China. Through parallel development pathways, the company aims to accelerate the AK0406 program as an additional option for influenza prevention, addressing challenges posed by viral evolution and limited vaccine protection, including in populations at high-risk of severe disease.

About ArkBio

ArkBio is a commercial-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for treatment of respiratory/lung and pediatric diseases. Founded in 2014, the company has established proprietary technology platforms and a differentiated innovative R&D pipeline through internal innovation and strategic collaborations.

Key R&D pipeline assets include: ziresovir (AK0529), the first direct-acting antiviral for RSV with positive phase III results; AK3280, a potentially best-in-class anti-fibrotic agent with positive phase II results for treatment of idiopathic pulmonary fibrosis, currently in a phase III trial; AK0901, approved and commercialized in China for ADHD treatment. The company also has multiple first-in-class or best-in-class innovative drug candidates under clinical or preclinical development.

ArkBio has established strategic partnerships with multinational and domestic pharmaceutical companies including Roche, Genentech, and Qilu Pharmaceutical; leading academic institutions including The Scripps Research Institute and the Institute of Microbiology, Chinese Academy of Sciences; and other domestic and international biotech companies and CROs.

For more information, please visit: www.arkbiosciences.com

Investor Inquiries: [email protected]

SOURCE Arkbio

Share this article

LONDON, Oct. 12, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, LLP continues to grow its London Energy & Natural Resources Practice with the addition of Hannah Roscoe as a shareholder. Roscoe advises clients across the energy and infrastructure sectors on mergers and acquisitions (M&A), joint ventures, commercial arrangements, restructurings, financings, and project development.

Roscoe's arrival follows the recent addition of Sofiya Bumagin, who joined Greenberg Traurig's London Energy & Natural Resources Practice from Sidley Austin. The two hires add complementary transactional capabilities to the firm's London offering, with Roscoe advising on energy M&A, project development, and commercial matters, and Bumagin focusing on infrastructure M&A and investments for private equity firms and other private capital providers.

Greenberg Traurig Executive Chairman Richard A. Rosenbaum said: "The firm's strategic focus on energy and infrastructure across the globe is in part driven by the continued growth and excellence of our London team. Hannah's arrival is another example of our investment in leading talent in these important sectors. She brings a strong track record across M&A, project development, and financing. Together with the addition of Sofiya Bumagin, her arrival further strengthens our ability to support clients on complex energy and infrastructure matters across jurisdictions."

Roscoe's experience includes battery storage transactions, biomass plant restructurings, and matters relating to green hydrogen. Recent mandates include a landmark financing of a synchronous condenser portfolio, the sale of an onshore wind farm, acquisitions involving battery storage units, and the restructuring of highway businesses.

Executive Vice President and London Managing Shareholder Fiona Adams said: "Hannah's arrival is an important addition to our London platform and reflects the breadth of experience we are continuing to develop across energy and infrastructure. Her practice covers many of the areas where clients are navigating investment and change, from energy transition and infrastructure development to M&A and restructuring. Alongside Sofiya's private capital and infrastructure investment experience, Hannah adds another dimension to the transactional capabilities we can offer clients from London and through our global network."

Roscoe will work closely with London Energy Practice Head Shashank Krishna, advising investors and other market participants on energy and infrastructure transactions in the UK and internationally.

Krishna added: "Hannah brings broad experience across energy and infrastructure transactions, from M&A to project development and financings. Her sector knowledge and commercial perspective are highly complementary to the work already being developed in London, and her arrival gives us greater depth across energy and infrastructure transactions, from investment and development through to restructuring and other strategic matters. We look forward to working with Hannah as we continue to build our energy and infrastructure capabilities in London and globally."

Roscoe said: "Greenberg Traurig has developed an impressive international platform with deep capabilities across energy and infrastructure, including M&A and private capital. The opportunity to join the firm as it continues to invest in its London practice was particularly attractive. I look forward to working with Shashank and colleagues across the firm's global network on strategic transactions, investments, and projects."

About Greenberg Traurig: Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm's broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI "Best of the Best Recommended Law Firm" by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com.

SOURCE Greenberg Traurig, LLP

Share this article

GCCL and LabConnect Sign MOU to Expand Global Clinical Trial Collaboration

Linking North American and Asia-Pacific Capabilities to Support Joint Sales and Project Execution

SEOUL, South Korea and RALEIGH, N.C., Oct. 12, 2026 /PRNewswire/ -- GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today that it signed a Memorandum of Understanding (MOU) with LabConnect on October 12 to expand global clinical trial collaboration. LabConnect is a global central laboratory and clinical trial samples solutions partner.

Built on a collaborative relationship spanning more than 20 years, this agreement aims to improve the operational efficiency of global clinical trial projects by linking the regional capabilities and expertise of both companies across North America and the Asia-Pacific (APAC) region.

The signing ceremony, held at GCCL's headquarters, was attended by key executives from both organizations, including GCCL CEO Kwan-goo Cho and from LabConnect, Jeff Mayhew, Founder and Strategic Commercial Advisor, and Joshua Gentile, Senior Vice President, Head of Commercial Sales and Marketing. During the event, the two companies shared their core services and future visions, discussing key collaborative initiatives, including:

- Identifying potential clients and supporting sales within each region

- Integrating global clinical trials and central laboratory services

- Cooperating on project management and client communications

- Formulating joint marketing strategies and identifying new business opportunities

Under this agreement, GCCL and LabConnect plan to establish a mutual collaboration framework leveraging their respective regional strengths and partner relationships. Furthermore, the companies intend to drive joint sales and marketing initiatives while setting up shared systems and processes for client responses and project management.

"Through this collaboration with GCCL, we expect to simplify and orchestrate complex studies conducted in South Korea and the Asia-Pacific region," said Jeff Mayhew, Founder and Strategic Commercial Advisor of LabConnect. "Pairing GCCL's laboratory and logistics strength with our global alliance of clinical and specialty laboratories, along with proactive sample logistics oversight and intervention, provides sponsors a more coordinated path for multi-regional studies."

Kwan-goo Cho, CEO of GCCL, stated, "This MOU marks the starting point of connecting GCCL's execution capabilities in the APAC region with LabConnect's comprehensive global alliance of clinical and specialty laboratories. We are committed to building a practical collaborative framework spanning joint sales, project execution, and client management to accelerate our global clinical trial business."

About LabConnect

LabConnect® is a global central laboratory services and clinical trial sample solutions partner, connecting the full sample journey, from biomarker strategy and custom kitting through testing, storage, and submission-ready data. The company combines scientific and operational expertise, its global alliance of clinical and specialty laboratories, worldwide logistics oversight, and integrated data services to support routine and specialized testing across complex global studies. LabConnect helps pharmaceutical, biotechnology, and contract research organizations reduce operational risk, improve study predictability, and generate meaningful insights from each sample. Visit LabConnect.com.

About GCCL

GCCL, a subsidiary of the GC Group, is a leading clinical trial sample analysis provider offering an integrated "one-stop lab solution" with central, bioanalysis, and BSL-3 labs under one system. With tailored solutions, GCCL delivers precise and efficient analytical services across all phases of clinical trials, solidifying its position as a trusted partner in new drug development. Leveraging advanced platforms and LIMS, the company supports partners across Asia and beyond with customized and compliant solutions. In recognition of its leadership, GCCL recently received Frost & Sullivan's 2025 Best Practices Customer Value Leadership Award in the Asia-Pacific clinical sample analysis services industry.

SOURCE LabConnect

Share this article

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

If you are a long-term EXEL stockholder please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. The consultation and case are free with no obligation to you. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:

Kuehn Law, PLLC

Justin Kuehn, Esq.

53 Hill Street, Suite 605

Southampton, NY 11968

[email protected]

(833) 672-0814

SOURCE Kuehn Law, PLLC

Share this article

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

The proposed transactions may contain terms that could limit superior competing offers.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Option Care Health, Inc. (NASDAQ: OPCH)'s sale to CD&R, McKesson Corporation for $32.05 per share. If you are an Option Care shareholder, click here to learn more about your rights and options.

Pacira BioSciences, Inc. (NASDAQ: PCRX)'s sale to Viatris Inc. for $36.50 per share in cash. If you are a Pacira shareholder, click here to learn more about your rights and options.

RXO Inc. (NYSE: RXO)'s sale to C.H. Robinson Worldwide, Inc. for $17.25 per share in cash and 0.0856 shares of C.H. Robinson common stock for each RXO share. Upon closing of the Proposed Transaction, RXO shareholders are expected to own 11% of the combined company. If you are a RXO shareholder, click here to learn more about your legal rights and options.

Boundless Bio, Inc. (NASDAQ: BOLD)'s merger with Serapha Bio, Inc. Upon closing of the proposed transaction, Boundless Bio shareholders are expected to own approximately 3.7% of the combined company. If you are a Boundless Bio shareholder, click here to learn more about your rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Halper Sadeh LLC

Daniel Sadeh, Esq.

Zachary Halper, Esq.

One World Trade Center

85th Floor

New York, NY 10007

(212) 763-0060

[email protected]

[email protected]

https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Share this article

Aeon joins Austin's leading deep tech companies following major defense contract awards, production milestones, and expansion of its manufacturing operations.

AUSTIN, Texas, Oct. 12, 2026 /PRNewswire/ -- Aeon Industrial, a vertically integrated defense manufacturer developing advanced missile systems, interceptors, and critical defense subsystems, has been named to the inaugural 2026 Austin Deep Tech 50, a list recognizing companies driving innovation and industrial growth in Central Texas.

The list was organized by Overmatch Ventures in partnership with seven leading venture capital firms: Valor Equity Partners, 8VC, Banner VC, B Capital, Ambition Capital, Ensemble VC, and Trust Ventures. The Austin Deep Tech 50 recognizes 50 of the region's most promising deep technology companies, highlighting the firms advancing critical technologies and shaping the next generation of American industry.

Aeon's selection follows a series of major milestones as the company expands its defense manufacturing capabilities and scales production for the U.S. military, allied nations, and defense industry customers. The company also delivered ahead of schedule on a complex U.S. Army contract involving the development of an all-up weapon system and warhead, as well as successful live testing.

In recent weeks, Aeon has secured a key eight-figure defense contract, placed more than 10,000 of its MERC high-voltage electronic safe-and-arm devices into production following successful performance at the Department of War's Drone Dominance initiative, and earned selection in the U.S. Army's interceptor challenge with its layered air and missile defense architecture.

"America needs a defense industrial base capable of producing advanced weapons at the scale and cost required to meet today's threats," said Naweed Tahmas, Founder and CEO of Aeon Industrial. "We're building that capability here in Austin. Being recognized for advancing American manufacturing and deep technology is a testament to our team and the industrial ecosystem taking shape in Texas."

Aeon is expanding production at its new 140,000-square-foot manufacturing facility in Cedar Park, Texas, just outside Austin. The facility brings missile systems, interceptors, propulsion, fuzing, software, and assembly under one roof, enabling Aeon to manufacture complete weapon systems and critical subsystems at industrial scale for government and industry customers.

Aeon's core portfolio includes Zeus, a lightweight, software-defined tactical missile system designed for shoulder-fired use and integration across ground, air, and maritime platforms. Zeus features interchangeable sensors and warheads, enabling a single system to address a wide range of threats, from drones to armored vehicles. The company also manufactures MERC, a low-cost, high-voltage electronic safe-and-arm device supporting time, proximity, and impact fuzing across drones, missiles, and interceptors. Both products are designed for affordability, scalability, and high-volume production.

Aeon's vertically integrated manufacturing model is designed to reduce costs, accelerate production timelines, and deliver affordable mass to the U.S. military, allied nations, and defense industry customers.

About Aeon Industrial

Aeon Industrial is a vertically integrated defense manufacturer developing and producing advanced strike systems and critical subsystems at industrial scale. From its 140,000-square-foot manufacturing facility, Aeon brings weapon design and production under one roof, including propulsion, fuzing, autonomy and other critical subsystems. Led by former special operators, senior government officials and experienced aerospace and defense engineers, Aeon is a trusted partner to U.S. government customers and industry.

SOURCE Aeon Industrial

Share this article

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

If you are a long-term IMVT stockholder please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. The consultation and case are free with no obligation to you.Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:

Kuehn Law, PLLC

Justin Kuehn, Esq.

53 Hill Street, Suite 605

Southampton, NY 11968

[email protected]

(833) 672-0814

SOURCE Kuehn Law, PLLC

Share this article